Artificial intelligence is rapidly reshaping drug discovery as pharmaceutical and biotech companies race to shorten costly R&D timelines and improve success rates. More than 200 startups are now competing to embed AI directly into research workflows, drawing intense investor interest.

One of the frontrunners is Converge Bio, a Boston- and Tel Aviv–based startup that recently raised $25 million in an oversubscribed Series A round led by Bessemer Venture Partners, with participation from TLV Partners, Saras Capital, Vintage Investment Partners, and executives from firms including Meta and OpenAI. The funding highlights growing confidence in AI-led drug development.

Converge Bio applies generative AI trained on molecular data—DNA, RNA, and proteins—to accelerate multiple stages of drug development, from target discovery to manufacturing and clinical trials. Its platform delivers integrated, ready-to-use systems rather than standalone models, including tools for antibody design, protein yield optimization, and biomarker discovery.

Since its $5.5 million seed round in 2024, the company has completed over 40 programs with pharmaceutical and biotech clients across North America, Europe, and Israel, while rapidly expanding its team. Case studies show major performance gains, including significant increases in protein yield and highly potent antibody generation.

The company’s rise mirrors a broader industry shift toward data-driven molecular design, reinforced by breakthroughs such as AlphaFold and major pharma–AI collaborations. While challenges like model validation remain, Converge Bio mitigates risk by pairing generative models with predictive systems. Its long-term goal is to become the foundational generative AI lab for the life sciences industry.